{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:02:45Z","timestamp":1793106165899,"version":"4.5.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2025.1638241","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:21:38Z","timestamp":1750742498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Editorial: Chronic hepatitis B management: current status and future directions"],"prefix":"10.3389","volume":"12","author":[{"given":"Ivana","family":"Lazarevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/pathogens13040291","article-title":"Prospects for controlling hepatitis B globally","volume":"13","author":"Soriano","year":"2024","journal-title":"Pathogens."},{"key":"B2","unstructured":"Geneva\n          World Health Organization\n          Hepatitis B\n          \n          2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-0039-3401031","article-title":"Role of biomarkers in guiding cure of viral hepatitis B","volume":"40","author":"Buti","year":"2020","journal-title":"Semin Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.17272","article-title":"Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone","volume":"57","author":"Wang","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"636897","DOI":"10.3389\/fmicb.2021.636897","article-title":"multifaceted interaction between hepatitis b virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"24066","DOI":"10.1021\/acsomega.2c02216","article-title":"cccDNA-A culprit and stumbling block for the hepatitis b virus infection: its presence in hepatocytes perplexed the possible mission for a functional cure","volume":"7","author":"Bhat","year":"2022","journal-title":"ACS Omega."},{"key":"B8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/v13060951","article-title":"Novel biomarkers of hepatitis B virus and their use in chronic hepatitis b patient management","volume":"13","author":"Vachon","year":"2021","journal-title":"Viruses."},{"key":"B10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/jmv.22014","article-title":"Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents","volume":"83","author":"Cheng","year":"2011","journal-title":"J Med Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/jvh.12899","article-title":"Identified OAS3 gene variants associated with coexistence of HBsAg and anti-HBs in chronic HBV infection","volume":"25","author":"Wang","year":"2018","journal-title":"J Viral Hepat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7754\/Clin.Lab.2020.200412","article-title":"Virology and serological characteristics of chronic hepatitis B patients with the co-existence of HBsAg and anti-HBs antibodies","volume":"66","author":"Zhu","year":"2020","journal-title":"Clin Lab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/pathogens13010046","article-title":"Hepatitis B surface antigen isoforms: their clinical implications, utilisation in diagnosis, prevention and new antiviral strategies","volume":"13","author":"Lazarevic","year":"2024","journal-title":"Pathogens."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1638241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:21:40Z","timestamp":1750742500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1638241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":13,"alternative-id":["10.3389\/fmed.2025.1638241"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1638241","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1638241"}}